Health care stocks were mixed pre-bell Thursday, with The Health Care Select Sector SPDR Fund (XLV) marginally lower and the iShares Biotechnology ETF (IBB) up 0.5%.
UnitedHealth Group (UNH) is facing a criminal investigation by the US Department of Justice over possible Medicare fraud tied to its Medicare Advantage operations, The Wall Street Journal reported, citing people familiar with the matter. The company's shares were down past 8% premarket.
Biohaven (BHVN) stock was more than 11% lower after the company said Wednesday that the US Food and Drug Administration's Office of Neuroscience is extending the Prescription Drug User Fee Act, or PDUFA, date for troriluzole's new drug application for the treatment of spinocerebellar ataxia by three months.
Mesoblast (MESO) shares were up over 7% after the company said overnight it received seven years of orphan drug exclusivity from the US Food and Drug Administration for Ryoncil, a treatment approved for steroid-refractory acute graft versus host disease in children aged two months and older.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.